Overview

3BNC117 and 10-1074 in HIV Uninfected Adults

Status:
Completed

Trial end date:
2018-01-09

Target enrollment:

Participant gender:

Summary

This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human immunodeficiency virus (HIV)-uninfected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use as prophylaxis against HIV infection in healthy HIV-uninfected individuals at risk for HIV infection.

Phase:

Phase 1

Details

Lead Sponsor:

Rockefeller University

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins